Analyst upgrades and bullish initiations drive SCTX surge
- Wells Fargo upgraded to Overweight with $60 PT on Aug 19
- Guggenheim raised to Strong-Buy at $50; Leerink Outperform at $37
- Consensus now Strong Buy with ~$49 avg target vs ~$27 price
- Praise for ELXR epigenetic CRISPR platform for durable PCSK9 silencing
- One-time LDL-C reduction therapy avoids permanent DNA edits
- First-in-human data expected H1 2027 as major catalyst
- Recent insider buying by executives added to positive sentiment
- Stock hit new 52-week high, extending post-July IPO rally
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.